Previous 10 | Next 10 |
MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced p...
Sight Sciences, Inc. (SGHT) Q2 2021 Earnings Conference Call August 13, 2021 05:00 PM ET Company Participants Philip Taylor - IR Paul Badawi - CEO Jesse Selnick - CFO Conference Call Participants Cecilia Furlong - Morgan Stanley Presentation Operator Good day Ladies and gentlemen, and welcome...
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ende...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company’s management will discuss the results durin...
Shares of Sight Sciences Inc. (NASDAQ:SGHT) traded today at $38.36, eclipsing its 52-week high. This new high was reached on below average trading volume as 119,000 shares traded hands, while the average 30-day volume is approximately 365,000 shares. Sight Sciences Inc is a growth-stage ...
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye diseases, today announced that data from multiple retrospective and prospec...
Medical device maker Sight Sciences (SGHT) closed its IPO and raised about $276M in gross proceeds.The eye-disease focused company sold 11.5M common shares, including the exercise in full of the underwriters’ option to by 1.5 additional shares, at $24 each.The company's stock...
MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases, today announced the ...
Sight Sciences has two innovative products to address eye diseases. Commercial traction is good, from a low sales base, as the potential is large. While the valuation is high, the potential is very large as well, making me interested in the name. For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of c...
2024-06-17 00:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of ...